A Phase 2 interventional study of TransCon PTH and Placebo for TransCon PTH in Hypoparathyroidism, Endocrine System Diseases and Parathyroid Diseases, sponsored by Ascendis Pharma A/S. Completed at 15 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Ascendis Pharma A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Hypoparathyroidism with a site in United States — 8 open to participants now, 12 under way, 5 of them phase 3. Hypoparathyroidism · United States.
Among the 43 studies in Hypoparathyroidism with a site in United States, this one is the 14th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2019, is one of 9 in phase 2, and was the 24th registered.
128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.
Browse Hypoparathyroidism studies →8 of the 43 studies in Hypoparathyroidism with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Calcilytix Therapeutics, Inc., a BridgeBio company · Sites in United States, Canada, Japan
Ages 16+
MBX Biosciences · Sites in United States, Canada
Ages 18+
Ascendis Pharma Bone Diseases A/S · Sites in United States
Ages 18+
Ascendis Pharma A/S · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Hypoparathyroidism studies recruiting now, 19 (73%) set no upper age limit and 5 (19%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 14 · Phase 4 3
First in 1991; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is above the median of 50 across 77 interventional studies indexed under Hypoparathyroidism.
Median enrollment 41 across the 34 interventional studies, 95 across the 9 observational. Of the 29 that completed or were terminated, 22 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 43 have an industry lead sponsor. The 10 most frequent:
Ascendis Pharma A/S is the lead sponsor of 17 studies on the registry; 7 are open to participants now.
Ascendis Pharma A/S has 4 studies filed under Hypoparathyroidism — fewer than ten, so there is no comparison to draw.
3 of the studies in Hypoparathyroidism with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07081997Phase 3Ascendis Pharma Bone Diseases A/SA Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism | 2027-06 |
| NCT05793853Columbia UniversityHypoparathyroidism Natural History Study | 2026-12 |
| NCT07264634Ascendis Pharma A/SA Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide) | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies in Hypoparathyroidism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
During the first four weeks of the trial, participants were randomly assigned to one of four groups: three groups received fixed doses of TransCon PTH and one group received placebo. TransCon PTH or placebo were administered as a subcutaneous injection using a pre-filled injection pen. Neither trial participants nor their doctors know who has been assigned to each group. After the four weeks, participants continued in the trial as part of a long-term extension period. During the extension, all participants received TransCon PTH, with the dose adjusted to their individual needs. This was a global trial that was conducted in the United States, Canada, Germany, Denmark, Italy and Norway.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
On a stable dose for at least 12 weeks (or 4 weeks if on Natpara as of September 2019) prior to Screening of:
Optimization of supplements prior to randomization to achieve the target levels of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TransCon PTH 15 mcg delivered once daily by subcutaneous injection
Combination Product: TransCon PTH
TransCon PTH 18 mcg delivered once daily by subcutaneous injection
Combination Product: TransCon PTH
TransCon PTH 21 mcg delivered once daily by subcutaneous injection
Combination Product: TransCon PTH
Placebo mimicking 15, 18, or 21 mcg of TransCon PTH delivered once daily by subcutaneous injection
Combination Product: Placebo for TransCon PTH
Participants who completed the 4-week double-blind period, continued into the open-label extension period and received treatment with TransCon PTH up to Week 266, with up to an initial 14 weeks of TransCon PTH titration and standard of care optimization, followed by approximately 248 weeks of individualized doses of TransCon PTH (allowable dose range: 6 to 60 mcg/day).
Combination Product: TransCon PTH
TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
Efficacy - Primary Endpoint During the Blinded Period
The percentage of subjects with albumin-adjusted serum calcium within the normal range, and spot morning fractional excretion of calcium (spot AM FECa) within normal range (≤2%) or a reduction by at least 50% from baseline, and not taking active vitamin D supplements, and taking ≤1000 mg/day of calcium supplements
Time frame: Week 4
Efficacy - Key Secondary Endpoint During the Blinded Period
The percentage of subjects with albumin-adjusted serum calcium within the normal range, and spot AM FECa within the normal range (≤2%) or a reduction by at least 50% from baseline, and not taking active vitamin D supplements, and taking ≤ 500 mg/day of calcium supplements
Time frame: Week 4
| Milestone | Double Blind: TransCon PTH 15 mcg | Double Blind: TransCon PTH 18 mcg | Double Blind: TransCon PTH 21 mcg | Double Blind: Placebo | Open-Label Extension Period: TransCon PTH |
|---|---|---|---|---|---|
| Started | 14 | 15 | 15 | 15 | 0 |
| Completed | 14 | 15 | 15 | 15 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Double Blind: TransCon PTH 15 mcg | Double Blind: TransCon PTH 18 mcg | Double Blind: TransCon PTH 21 mcg | Double Blind: Placebo | Open-Label Extension Period: TransCon PTH |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 59 |
| Completed | 0 | 0 | 0 | 0 | 56 |
| Not completed | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 1 |
The percentage of subjects with albumin-adjusted serum calcium within the normal range, and spot morning fractional excretion of calcium (spot AM FECa) within normal range (≤2%) or a reduction by at least 50% from baseline, and not taking active vitamin D supplements, and taking ≤1000 mg/day of calcium supplements
| Percentage of participants | TransCon PTH 15 mcg | TransCon PTH 18 mcg | TransCon PTH 21 mcg | Placebo |
|---|---|---|---|---|
| Efficacy - Primary Endpoint During the Blinded Period | 50.0 (23.0 to 77.0) | 40.0 (16.3 to 67.7) | 60.0 (32.3 to 83.7) | 26.7 (7.8 to 55.1) |
The percentage of subjects with albumin-adjusted serum calcium within the normal range, and spot AM FECa within the normal range (≤2%) or a reduction by at least 50% from baseline, and not taking active vitamin D supplements, and taking ≤ 500 mg/day of calcium supplements
| Percentage of participants | TransCon PTH 15 mcg | TransCon PTH 18 mcg | TransCon PTH 21 mcg | Placebo |
|---|---|---|---|---|
| Efficacy - Key Secondary Endpoint During the Blinded Period | 50.0 (23.0 to 77.0) | 26.7 (7.8 to 55.1) | 60.0 (32.3 to 83.7) | 20.0 (4.3 to 48.1) |
Collected over From Week 0 to Week 4 for double-blind treatment period and up to Week 266 for open label extension (OLE). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind: TransCon PTH 15 mcg | 0/14 (0%) | 0/14 (0%) | 6/14 (42.9%) |
| Double Blind: TransCon PTH 18 mcg | 0/15 (0%) | 0/15 (0%) | 5/15 (33.3%) |
| Double Blind: TransCon PTH 21 mcg | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Double Blind: Placebo | 0/15 (0%) | 0/15 (0%) | 6/15 (40%) |
| Total TransCon PTH Period | 0/59 (0%) | 8/59 (13.6%) | 57/59 (96.6%) |
| Event | Double Blind: TransCon PTH 15 mcg | Double Blind: TransCon PTH 18 mcg | Double Blind: TransCon PTH 21 mcg | Double Blind: Placebo | Total TransCon PTH Period |
|---|---|---|---|---|---|
| HypercalcaemiaMetabolism and nutrition disorders | 0/14 | 0/15 | 0/15 | 0/15 | 2/59 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/14 | 0/15 | 0/15 | 0/15 | 1/59 |
| Chronic sinusitisInfections and infestations | 0/14 | 0/15 | 0/15 | 0/15 | 1/59 |
| DehydrationMetabolism and nutrition disorders | 0/14 | 0/15 | 0/15 | 0/15 | 1/59 |
| Haemorrhage intracranialNervous system disorders | 0/14 | 0/15 | 0/15 | 0/15 | 1/59 |
| HeadacheNervous system disorders | 0/14 | 0/15 | 0/15 | 0/15 | 1/59 |
| Herpes zosterInfections and infestations | 0/14 | 0/15 | 0/15 | 0/15 | 1/59 |
| HypocalcaemiaMetabolism and nutrition disorders | 0/14 | 0/15 | 0/15 | 0/15 | 1/59 |
| HypokalemiaMetabolism and nutrition disorders | 0/14 | 0/15 | 0/15 | 0/15 | 1/59 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/14 | 0/15 | 0/15 | 0/15 | 1/59 |
| Event | Double Blind: TransCon PTH 15 mcg | Double Blind: TransCon PTH 18 mcg | Double Blind: TransCon PTH 21 mcg | Double Blind: Placebo | Total TransCon PTH Period |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/14 | 0/15 | 0/15 | 0/15 | 21/59 |
| HeadacheNervous system disorders | 3/14 | 1/15 | 1/15 | 1/15 | 16/59 |
| HypocalcaemiaMetabolism and nutrition disorders | 0/14 | 0/15 | 0/15 | 1/15 | 11/59 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/14 | 0/15 | 0/15 | 0/15 | 11/59 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/14 | 0/15 | 0/15 | 1/15 | 10/59 |
| HypertensionVascular disorders | 1/14 | 1/15 | 0/15 | 0/15 | 10/59 |
| ParaesthesiaNervous system disorders | 0/14 | 0/15 | 0/15 | 1/15 | 9/59 |
| NauseaGastrointestinal disorders | 2/14 | 1/15 | 1/15 | 1/15 | 7/59 |
| FatigueGeneral disorders | 0/14 | 1/15 | 1/15 | 0/15 | 8/59 |
| DizzinessNervous system disorders | 0/14 | 2/15 | 0/15 | 0/15 | 6/59 |
| Age, Continuous(years) | TransCon PTH 15 mcg | TransCon PTH 18 mcg | TransCon PTH 21 mcg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 47.03 ± 13.230 | 46.58 ± 11.157 | 53.67 ± 11.287 | 51.80 ± 12.345 | 49.82 ± 12.094 |
| Sex: Female, Male(Participants) | TransCon PTH 15 mcg | TransCon PTH 18 mcg | TransCon PTH 21 mcg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 12 | 12 | 12 | 12 | 48 |
| Male | 2 | 3 | 3 | 3 | 11 |
| Ethnicity (NIH/OMB)(Participants) | TransCon PTH 15 mcg | TransCon PTH 18 mcg | TransCon PTH 21 mcg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 14 | 15 | 14 | 15 | 58 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | TransCon PTH 15 mcg | TransCon PTH 18 mcg | TransCon PTH 21 mcg | Placebo | Total |
|---|---|---|---|---|---|
| Asian | 0 | 0 | 2 | 0 | 2 |
| White | 14 | 12 | 13 | 15 | 54 |
| Other | 0 | 3 | 0 | 0 | 3 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 | 0 | 0 |
| Height(cm) | TransCon PTH 15 mcg | TransCon PTH 18 mcg | TransCon PTH 21 mcg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 166.92 ± 8.806 | 166.71 ± 8.385 | 165.37 ± 10.961 | 164.07 ± 10.368 | 165.75 ± 9.520 |
| Weight(kg) | TransCon PTH 15 mcg | TransCon PTH 18 mcg | TransCon PTH 21 mcg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 76.58 ± 22.479 | 80.04 ± 11.279 | 72.26 ± 18.621 | 76.43 ± 14.256 | 76.32 ± 16.869 |
| Body Mass Index(kg/m^2) | TransCon PTH 15 mcg | TransCon PTH 18 mcg | TransCon PTH 21 mcg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 27.08 ± 5.723 | 28.76 ± 3.148 | 26.12 ± 4.647 | 28.30 ± 3.775 | 27.57 ± 4.415 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Mar 2020, 6 months.
Results were first posted in Sep 2023, 3 years 5 months after primary completion. A results delay was requested in Mar 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palopegteriparatide
Ascendis Pharma A/S